HER2-positive breast cancer is considered an immunogenic tumor, and the host immune response in this breast cancer subtype has been extensively explored due to its known role in modulating the activity of anti-HER2 agents [e.g., through antibody-dependent cellular cytotoxicity (ADCC)]7,8. The gene discussed is ERBB2; the disease is neoplasm.